What Is the Role of Maintenance Rituximab in Follicular NHL?

Size: px
Start display at page:

Download "What Is the Role of Maintenance Rituximab in Follicular NHL?"

Transcription

1 Review Article [1] January 01, 2008 By David G. Maloney, MD, PhD [2] Recent trials have demonstrated improvements in progression-free and overall survival with the inclusion of the chimeric anti-cd20 monoclonal antibody rituximab (Rituxan) in chemotherapy regimens for treatment-naive and relapsed patients with advanced-stage follicular non-hodgkin's lymphoma (NHL). As rituximab therapy has significant single-agent activity in follicular NHL, is generally well tolerated, and has no dose-limiting or significant hematologic toxicity, a number of approaches evaluating maintenance therapy with extended dosing of rituximab are being tested. Trials have demonstrated prolonged progression-free survival in patients treated with maintenance rituximab using a variety of schedules following treatment with single-agent rituximab, induction or salvage chemotherapy, or salvage therapy with rituximab and chemotherapy combinations. Small increases in neutropenia and infections have been reported with extended rituximab use. Ongoing trials are evaluating the optimal use of rituximab (maintenance vs retreatment) and the benefit of rituximab maintenance following treatment of therapy-naive patients treated with rituximab-containing chemoimmunotherapy induction regimens. This article discusses the risks and benefits of maintenance rituximab for follicular NHL. Immunotherapy with the chimeric anti-cd20 monoclonal rituximab (Rituxan) has rapidly gained acceptance in both initial and salvage therapy for patients with follicular lymphoma (FL). Chemoimmunotherapy with regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], prednisone), R-CVP (rituximab, cyclophosphamide, vincristine, prednisone), or R-MCP (rituximab, mitoxantrone, chlorambucil [Leukeran], prednisone) have been associated with improved outcomes, including longer duration of remissions and improvements in overall survival (OS).[1-3] Several factors have contributed to this remarkable success. These include significant single-agent activity with acceptable infusion-related toxicity and, most critically, a lack of significant overlapping toxicity when rituximab is administered simultaneously or following conventional chemotherapy. This favorable benefit-to-risk ratio has led to studies using extended rituximab dosing as maintenance therapy following a variety of induction treatments. Nearly all such studies have demonstrated a benefit to maintenance therapy. This review will address the principles of maintenance therapy and the current data concerning the risks and benefits of the use of maintenance therapy with rituximab for patients with FL. Defining 'Maintenance' Therapy One of the difficulties in addressing this issue is a lack of definition of what constitutes "maintenance" therapy. In practice, there are two situations included in this category. In one case, rituximab is given as maintenance following an induction treatment regimen containing rituximab. This would include treatment with single-agent rituximab or the use of a rituximab-containing immunochemotherapeutic regimen. In the other situation, prolonged rituximab therapy is given following initial treatment with regimens not containing rituximab. This can also be thought of as sequential therapy. In this latter situation it is perhaps not as surprising that treatment with rituximab following chemotherapy would be better than chemotherapy alone as rituximab produces high levels of single-agent activity (50% 70%) in patients with de novo or relapsed FL. Principles of Maintenance Therapy Several principles contribute to the effectiveness of maintenance therapy. Obviously, maintenance treatment is neither necessary nor effective in patients cured by the primary treatment. In fact, the more effective the primary treatment is, the more difficult it may be to prove the effectiveness of a maintenance strategy. Effective treatments lead to a reduced frequency of or a delay in time until relapse, and may require larger studies or longer duration of maintenance and follow-up to prove benefit. Conversely, the effects of maintenance therapy with an active agent may be easier to Page 1 of 9

2 demonstrate when a high frequency and rate of events are observed following the induction therapy. In follicular non-hodgkin's lymphoma (NHL), which is not currently considered curable by initial therapy, an increased rate/frequency of relapse is observed in a number of situations. These include the treatment of patients at higher risk (ie, higher Follicular Lymphoma International Prognostic Index [FLIPI] scores at diagnosis), treatment of relapsed patients (shorter expected subsequent remission rate and duration), and the use of less effective treatment regimens (lower response rates, complete response [CR] rates, and duration of remission). A second important concept is that the disease must initially be, and must remain, sensitive to the agents given for maintenance. Thus, treatment of a population already resistant to the maintenance therapy is not beneficial and only exposes patients to the continued risks of the therapy. Development of Resistance to Rituximab It is clear that resistance to rituximab may be present at the time of initial therapy or may develop following rituximab exposure. In our initial trials with rituximab for relapsed indolent NHL, 48% of patients had a documented response (partial response [PR] plus CR) to treatment with infusions of 375 mg/m2 weekly for four doses, with a median time to progression for responding patients of approximately 1 year.[4,5] Thus, at least 50% of these relapsed patients had some level of resistance to initial therapy with this regimen. Furthermore, in a follow-up study, patients with a documented PR or CR to rituximab were then retreated upon disease progression with a second course of rituximab. All of these patients had previously responded with at least a PR or CR lasting more than 6 months, but only 40% had a documented response (PR or CR) to retreatment.[6] Thus, 60% of these patients developed some level of resistance to retreatment following prior therapy with rituximab. However, it is also true that only a minority of patients actually developed progressive disease on therapy and many had some response (defined as less than a PR, but not progression) to retreatment. Thus, there may still be some benefit in these situations. In most cases, the mechanism of resistance to rituximab is poorly understood. Occasionally, this appears to be due to loss of the CD20 antigen,[7,8] but more often, antigen expression appears to persist, implying that the resistance must be due to either the loss of direct effects (cell signaling, growth inhibition, apoptosis) or to acquired resistance to the immune effector functions of antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).[9] In the context of a discussion on maintenance therapy, the question is: When during the course of therapy did this acquired resistance develop? Unfortunately, little information is currently available to help answer this question. Patients with progressive disease while receiving rituximab maintenance, by definition, will be rituximab-refractory/resistant. It is reasonable to assume (but not proven) that patients refractory to rituximab therapy are unlikely to derive substantial benefit from rituximab maintenance therapy. As discussed below, it is not known how treatment with maintenance rituximab will influence the emergence of rituximab-resistant clones, nor what the clinical implications of this would be on subsequent therapy. Maintenance Therapy After Single-Agent Rituximab Our initial experience with single-agent rituximab for relapsed FL using a single dose and the weekly dose 4 schedules did not identify a maximally tolerated dose or dose-limiting toxicity.[10,11] Further dose escalation was initially limited by drug availability. A subsequent study utilized eight weekly infusions for patients with relapsed FL, producing a similar response rate and duration of response to the weekly 4 doses.[12] Recent studies have clearly demonstrated that giving additional rituximab on an extended schedule can prolong remission durations. A phase II study evaluated treatment with repeated courses of rituximab (375 mg/m2 weekly 4), given at 6-month intervals for up to 2 years, to patients with stable or responding disease at 3 months following an initial course of rituximab.[13] Patients in this study had not received any prior therapy and had FL or small lymphocytic lymphoma. The time to disease progression was more than 34 months for the patients with FL, which is longer than reported outcomes of a single course of rituximab in patients with low tumor bulk.[14] Continued improvement in response was observed throughout the maintenance treatments. A randomized study by the Swiss Group for Clinical Cancer Research (SAKK) provided more conclusive evidence. This trial evaluated patients with FL who were treated with four doses of rituximab on the usual weekly schedule.[15,16] Patients with at least stable disease were then Page 2 of 9

3 randomized to observation vs an additional infusion of rituximab (375 mg/m2) at months 3, 5, 7, and 9. The extended schedule resulted in prolongation of time to progression, both for patients without prior chemotherapy and for relapsed patients. Interestingly, there was no greater improvement in the response rate (PR, CR, or conversion of PR to CR) in the maintenance group compared with the observation group, with both arms demonstrating improvement following the initial evaluation time at 12 weeks from the start of treatment. In this randomized study, the benefit of maintenance was limited to patients with a documented response (PR or CR) to the initial rituximab treatment. An advantage of using maintenance rituximab following initial treatment with rituximab is that one can judge the response to the initial rituximab and restrict the administration of maintenance to those who are sensitive to rituximab and who will receive the most benefit. This may make such an approach even more cost-effective. Maintenance Rituximab vs Retreatment With Rituximab at Relapse It is unclear whether it is better to prevent relapse with maintenance therapy or to reserve rituximab for retreatment of patients at the time of progression. One small clinical study has compared these two approaches.[17] Patients with at least stable disease after a course of four infusions of rituximab were randomized to receive maintenance rituximab (four weekly infusions of 375 mg/m2, every 6 months for up to 2 years), vs retreatment with four weekly infusions of rituximab at the time of relapse. Patients responding to the retreatment were then observed until subsequent relapse and then treated again with a course of rituximab. The endpoints of the study, among others, included rituximab utilization (number of doses with each schema), duration of rituximab benefit, and response state and duration. Not surprisingly, patients treated with maintenance rituximab enjoyed longer durations of remissions, and a greater percentage of patients remained in remission. In contrast, the retreatment group, as expected, experienced more frequent relapses. However, at the end of the study there was no difference in the duration of rituximab benefit. At the time of reporting, there was an increased use of rituximab in the maintenance group, but this difference was continuing to diminish as patients in the retreatment group continued to receive therapy at subsequent progressions. Although this study did not demonstrate any definitive results, many investigators believe that the maintenance approach offers advantages, as the patient enjoys more prolonged clinical remissions. Opponents argue that maintenance costs, including drug and administration fees, make it difficult to justify this approach unless there is more definitive proof of benefit such as an improvement in overall survival. A large US national trial is currently evaluating rituximab maintenance in patients with indolent NHL and low tumor burden (using Groupe d'etude des Lymphomes Folliculaire [GELF] criteria) who respond to an initial course of rituximab. The Eastern Cooperative Oncology Group (ECOG) 4402-R, extended schedule or retreatment trial (RESORT), is randomizing these patients to continued treatment with rituximab (375 mg/m2) every 3 months until tumor progression vs retreatment with a course of rituximab at the time of tumor progression. This study is designed to determine which strategy leads to the most benefit and delays the time to the development of resistance to rituximab. Maintenance Rituximab After Chemotherapy Induction One large US trial (ECOG E1496) evaluated treatment with rituximab (375 mg/m2 weekly 4) every 6 months for up to 2 years for patients with stable or responding disease after treatment with either CVP or CF (cyclophosphamide, fludarabine) induction.[18] The CF arm was closed early following excess deaths associated with the chemotherapy. In FL patients after administration of CVP, the use of extended rituximab delayed the time to progression and was associated with a borderline improvement in overall survival. At 4 years, progression-free survival (PFS) for maintenance vs observation was 56% vs 33% and overall survival was 88% vs 72%, respectively. Patients in all risk groups benefited from sequential rituximab, but the greatest benefit was observed in patients with high tumor burden at the start of chemotherapy and minimal disease following chemotherapy. Interestingly, in data presented at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO), extended rituximab did not improve the outcome of patients in the small randomized subset of patients treated with CF induction chemotherapy.[19] The reason for this is not clear but appears to be associated with the higher CR rate of patients responding to this regimen and the lower number of events observed even in the patients assigned to observation. These "deeper" CRs may have decreased the frequency of relapse events so that a limited course of Page 3 of 9

4 rituximab maintenance would not have shown an effect. Rituximab Maintenance Following Rituximab/Chemotherapy Induction The administration of rituximab maintenance therapy after induction with rituximab plus chemotherapy is becoming the most relevant situation in this setting, as most patients are now initially treated with the combination. Multiple randomized studies have demonstrated that rituximab added to CVP, CHOP, or MCP is superior (longer PFS and OS) to treatment with chemotherapy alone.[1-3] Is there a role for additional maintenance rituximab in this setting? Two trials have been reported evaluating this approach in patients with relapsed FL. In a study by the German Low-Grade Lymphoma Study Group, maintenance rituximab was evaluated following R-FCM (rituximab, fludarabine, cyclophosphamide, mitoxantrone) or FCM chemotherapy.[20,21] The FCM arm was closed early due to the superiority of R-FCM at interim analysis, and the majority of patients were then treated with R-FCM. Patients responding to the induction arm were subsequently randomized to observation vs maintenance rituximab (375 mg/m2 4 at months 3 and 9).[21] For 81 FL patients treated with R-FCM, maintenance therapy with rituximab was associated with prolongation of time to progression compared with observation (not reached vs 26 months, P =.035). In this study there was no significant increase in infections or toxicity associated with maintenance treatment. In a study by the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), patients with relapsed FL (who had received no prior anthracycline therapy or prior rituximab therapy) were randomized to R-CHOP vs CHOP.[22] Responding patients were subsequently randomized to observation vs rituximab maintenance (375 mg/m2 every 3 months for up to 2 years). This study demonstrated the superiority of R-CHOP over CHOP, and not surprisingly, the use of maintenance rituximab delayed the time to progression/relapse in patients treated with CHOP. However, maintenance rituximab also significantly delayed the time to progression in those treated with R-CHOP. Median PFS was 33.1 months for R-CHOP/observation and not reached for R-CHOP/rituximab maintenance (P =.004). For the entire group, maintenance therapy improved overall survival at 3 years (85% vs 77%, P =.011). Slightly greater neutropenia and an increase in grade III/IV infections (9% vs 2.4%, P =.009) were observed in the maintenance group, but there were no treatment-related deaths associated with maintenance. The key remaining question arising from these studies is whether these findings will be confirmed when rituximab maintenance is used following initial rituximab/chemotherapy induction in treatment-naive patients? Given the above data, it would seem reasonable to conclude that the results should be similar. However, it may be more difficult to demonstrate this benefit in the front-line setting since, among other reasons, patients generally have a much longer duration of remission following their initial therapy. Thus, there will be fewer events (relapses) expected in the first few years following treatment. The frequency and rate of events also depends on the efficacy of the initial treatment. Although they are difficult to directly compare, nonrandomized studies suggest that PFS may be longer following R-CHOP than after R-CVP.[2,3] As maintenance is usually given for a limited duration, it may not be sufficient to prevent late relapses following a more effective induction therapy. In addition, patients who relapse early following rituximab/chemotherapy are likely already resistant to rituximab and would likely not benefit from additional rituximab given as maintenance. This may make it more difficult to demonstrate the benefits of maintenance in the front-line setting after increasingly effective rituximab/chemotherapy combinations. The European Primary Rituximab and Maintenance (PRIMA) trial has now completed enrollment and is evaluating this question. Patients with treatment-naive FL were given a rituximab-containing chemotherapy combination (CHOP, CVP, FCM, MCP) and then randomized to observation vs rituximab maintenance (375 mg/m2 every 2 months for 2 years). The choice of chemotherapy was not randomized, and the majority of patients received the R-CHOP regimen. Results are eagerly awaited. It is interesting to speculate that if this trial had been conducted with less effective initial therapy (perhaps R-CVP or rituximab alone), a greater number and frequency of events would have been expected and the effects of maintenance easier to demonstrate. In the absence of contradicting data, however, many clinicians are using maintenance following rituximab/chemotherapy induction, especially for patients at higher risk of early relapse (eg, with high FLIPI scores, bulky tumor, etc). Potential Risks of Maintenance Rituximab Page 4 of 9

5 To date, only minimal infusion-related toxicity has been associated with the continued use of rituximab. However, as expected, extended rituximab administration does cause prolonged depletion of B cells from the peripheral blood and presumably from tissue compartments as well. In the SAKK trial, this finding was associated with decreases in serum immunoglobulin (Ig)M but not IgG.[15,16] In the HOVON study, IgG levels did not increase in the maintenance group, whereas they did in the observation group following CHOP or R-CHOP [22]. As discussed previously, increased neutropenia and an increase in treatable grade III/IV infections were associated with maintenance in this trial. One nonrandomized historical study reported severe hypogammaglobulinemia associated with serious infections in patients treated with fludarabine/rituximab combinations.[23] Patients with recurrent serious infections should have IgG levels checked, as IgG replacement may decrease their subsequent risk. This problem may increase with the use of maintenance rituximab. In addition, evidence suggests that the effects of rituximab impede the development of primary and secondary humoral immune responses.[24-26] This may have implications for the effectiveness of new vaccinations. Lastly, rituximab has been associated with the reactivation/progression of some chronic infections such as hepatitis B and, more recently, progressive multifocal leukoencephalopathy (PML), which may be fatal (US Food and Drug Administration [FDA] black box warning).[27,28] It is critical that studies evaluating maintenance rituximab look for and capture these events and that physicians counsel patients regarding these rare but serious and possibly fatal complications. A maintenance approach may also have a strong impact on psychological, social, economic, or other factors. Maintenance treatments require scheduled treatments in the infusion room at a time when the patient is in remission. This increases the overall cost of the drug and administration, requires time off work, and may add psychological stress. On the other hand, staying in remission and avoiding additional treatment also has a major psychological benefit for most patients with FL. In a few situations where this has been studied, the economic impact of delaying tumor relapse appears to outweigh the economic cost of maintenance.[29] Other potential risks, including the consequences of developing resistance to rituximab and the possible impact of this occurrence on subsequent treatments remain largely unknown. Comprehensive evaluation of these risks/benefits require well designed clinical trials with extended follow-up of patient outcome for both relapse and nonrelapse events. These risks suggest that, when possible, rituximab maintenance use should be guided by clinical trial results. Dose, Schedule, and Duration of Rituximab Maintenance As discussed above, a variety of administration schedules have been used for maintenance rituximab therapy. These have largely been empirically designed. One small trial involved pharmacokinetic analysis of antibody levels to guide the schedule of maintenance rituximab dosing.[30] A target of 25 μg/ml was empirically set, and single infusions of antibody were administered to keep the serum trough levels at or above this level. On average, following induction with four weekly doses of rituximab, additional rituximab was required every 2 to 3 months over the next year to achieve this result. Based on this study and the results of the SAKK trial mentioned above, most ongoing trials are evaluating maintenance with a single infusion of rituximab every 2 to 3 months for 2 years or longer. In contrast, earlier studies evaluated four weekly infusions of rituximab given every 6 months for 1 to 2 years. While pharmacokinetic data are not available from these trials, data from the trial mentioned in the preceding paragraph demonstrate that the median time to antibody levels < 25 μg/ml following four infusions of rituximab was 5 months.[30]reference GUIDE Therapeutic Agents Mentioned in This Article Chlorambucil (Leukeran) Cyclophosphamide Page 5 of 9

6 Doxorubicin Fludarabine Mitoxantrone Prednisone Rituximab (Rituxan) Vincristine Brand names are listed in parentheses only if a drug is not available generically and is marketed as no more than two trademarked or registered products. More familiar alternative generic designations may also be included parenthetically. As yet, no data suggest a benefit of using one schedule over another. However, based on the number of infusions required, most ongoing studies are adopting treatment with a single infusion every 2 to 3 months. Finally, the duration of optimal maintenance therapy is not known. Current trial data have been reported to a maximum of 2 years, and ongoing trials are evaluating longer maintenance durations. In the absence of safety data from longer-duration studies, a conservative approach seems prudent and maintenance treatment should be limited to a maximum of 2 years. Conclusions Extended rituximab therapy has been associated with prolonged PFS following chemotherapy or following rituximab induction for treatment-naive and relapsed patients with FL. In addition, maintenance rituximab improves PFS and OS of patients with relapsed FL who are treated with chemotherapy or rituximab/chemotherapy. Currently, the benefits of maintenance therapy appear to outweigh the risks. However, further data are needed to quantify the risks of hypogammaglobulinemia, neutropenia, and serious infections associated with extended maintenance. Ongoing trials will help define the optimal dose and schedule, and hopefully determine whether a maintenance approach is superior to retreatment at the time of relapse. Currently available data suggest that maintenance rituximab should be considered in many situations for most patients with FL, especially those with higher-risk disease. Most importantly, it is critical that investigators continue enrolling patients into definitive clinical trials to further analyze the risks and benefits of this approach. Financial Disclosure: Dr. Maloney is a consultant for Genentech, Biogen IDEC, Genmab, and GlaxoSmithKline. References: 1. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25: , Page 6 of 9

7 2. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106: , Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105: , Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (rituximab) anti-cd20 monoclonal antibody therapy in patients with relapsed low-grade non-hodgkin's lymphoma. Blood 90: , McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-cd20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16: , Davis TA, Grillo-Lopez AJ, White CA, et al: Rituximab anti-cd20 monoclonal antibody therapy in non-hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 18: , Alvaro-Naranjo T, Jaen-Martinez J, Guma-Padro J, et al: CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: A new case report and review of the literature. Ann Hematol 82: , Haidar JH, Shamseddine A, Salem Z, et al: Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol 70: , Jazirehi AR, Vega MI, Bonavida B: Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 67: , Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al: IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-hodgkin's lymphoma. J Clin Oncol 15: , Maloney DG, Liles TM, Czerwinski DK, et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-cd20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84: , Piro LD, White CA, Grillo-Lopez AJ, et al: Extended Rituximab (anti-cd20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-hodgkin's lymphoma. Ann Oncol 10: , Hainsworth JD, Litchy S, Burris HA 3rd, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 20: , Colombat P, Salles G, Brousse N, et al: Rituximab (anti-cd20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 97: , Ghielmini M, Rufibach K, Salles G, et al: Single agent rituximab in patients with follicular or mantle cell lymphoma: Clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: A study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 16: , Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103: , Hainsworth JD, Litchy S, Shaffer DW, et al: Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-hodgkin's Page 7 of 9

8 lymphoma a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23: , Hochster HS, Weller E, Gascoyne RD, et al: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B (abstract 349). Blood 106(11), Hochster H, Weller E, Gascoyne R, et al: Cyclophosphamide and fludarabine (CF) in anvanced indolent lymphoma: Results from the ECOG/CALGB intergroup E1496 trial (abstract 8004). J Clin Oncol 25(18S):442s, Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104: , Forstpointner R, Unterhalt M, Dreyling M, et al: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108: , van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108: , Cabanillas F, Liboy I, Pavia O, et al: High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: A frequently unrecognized and easily treatable complication. Ann Oncol 17: , Bearden CM, Agarwal A, Book BK, et al: Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phix174. Am J Transplant 5:50-57, Gonzalez-Stawinski GV, Yu PB, Love SD, et al: Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-cd20 monoclonal antibody (IDEC-C2B8, rituximab). Clin Immunol 98: , van der Kolk LE, Baars JW, Prins MH, et al: Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100: , Freim Wahl SG, Folvik MR, Torp SH: Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: Case report and review of the literature. Clin Neuropathol 26:68-73, Perceau G, Diris N, Estines O, et al: Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 155: , Maturi B, Mikhael JR, Dunlop WCN, et al: Maintenance therapy with rituximab for follicular lymphoma is cost-effective a Canadian perspective (abstract 343). Blood 108(11), Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 23: , Source URL: Page 8 of 9

9 Links: [1] [2] Page 9 of 9

Outcomes of Treatment in Slovene Follicular Lymphoma Patients

Outcomes of Treatment in Slovene Follicular Lymphoma Patients Original Study Outcomes of Treatment in Slovene Follicular Lymphoma Patients Tanja Juznic Setina, Simona Borstnar, Barbara Jezersek Novakovic Abstract The treatment outcomes of follicular lymphoma (FL)

More information

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma

Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating

More information

The role of rituximab for maintenance therapy in

The role of rituximab for maintenance therapy in COUNTERPOINTS Current Controversies in Hematology and Oncology Counterpoints Is Maintenance Therapy Necessary in Low-Grade Lymphoma? Maintenance therapy with rituximab has been shown to prolong progression-free

More information

ORIGINAL ARTICLE. Suresh Advani 1, Shubhadeep Sinha 2, Pankaj Thakur 3, Neetu Naidu 3, Sreenivas Chary 3, Ghanshyam Biswas 4, Vamsi Krishna Bandi 5

ORIGINAL ARTICLE. Suresh Advani 1, Shubhadeep Sinha 2, Pankaj Thakur 3, Neetu Naidu 3, Sreenivas Chary 3, Ghanshyam Biswas 4, Vamsi Krishna Bandi 5 58 ORIGINAL ARTICLE Efficacy, Safety and Immunogenecitystudy of Intravenous Infusion of Rituximab (Hetero) and Reference Medicinal Product (Rituximab, Roche) in Indian Patients of Follicular Lymphoma Preliminary

More information

Update: Non-Hodgkin s Lymphoma

Update: Non-Hodgkin s Lymphoma 2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)

More information

Open questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland

Open questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific

More information

Non Transplant-Related Treatment Options in Follicular Lymphoma

Non Transplant-Related Treatment Options in Follicular Lymphoma Biology of Blood and Marrow Transplantation 12:53-58 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0111$32.00/0 doi:10.1016/j.bbmt.2005.10.003 Non Transplant-Related

More information

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin

More information

Model-based optimization of rituximab dosing regimen in follicular non-hodgkin lymphoma

Model-based optimization of rituximab dosing regimen in follicular non-hodgkin lymphoma Model-based optimization of rituximab dosing regimen in follicular non-hodgkin lymphoma D. Ternant, E. Hénin, G. Cartron, M. Tod, G. Paintaud, P. Girard Introduction Objectives Introduction Rituximab in

More information

Rituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description

Rituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.96 Subject: Rituxan Hycela Page: 1 of 5 Last Review Date: September 15, 2017 Rituxan Hycela Description

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium rituximab 10mg/ml concentrate for infusion (MabThera ) Roche (No.330/06) 10 November 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above

More information

The Use and Effectiveness of Rituximab Maintenance in Patients with Follicular Lymphoma Diagnosed Between 2004 and 2007 in the United States

The Use and Effectiveness of Rituximab Maintenance in Patients with Follicular Lymphoma Diagnosed Between 2004 and 2007 in the United States The Use and Effectiveness of Rituximab Maintenance in Patients with Follicular Lymphoma Diagnosed Between 2004 and 2007 in the United States Loretta J Nastoupil, The University of Texas MD Anderson Cancer

More information

Mathias J Rummel, MD, PhD

Mathias J Rummel, MD, PhD I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track

More information

TRANSPARENCY COMMITTEE OPINION. 8 November 2006

TRANSPARENCY COMMITTEE OPINION. 8 November 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia

More information

The case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.

The case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc. The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation

More information

Current treatment strategies in follicular lymphomas

Current treatment strategies in follicular lymphomas 17 (Supplement 10): x155 x159, 2006 doi:10.1093/annonc/mdl253 Current treatment strategies in follicular lymphomas W. Hiddemann & M. Unterhalt Department of Internal Medicine III, University of Munich,

More information

Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma

Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma Annals of Oncology 16 (Supplement 2): ii99 ii104, 2005 doi:10.1093/annonc/mdi724 Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma M. Dreyling, C.

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate

More information

New Targets and Treatments for Follicular Lymphoma

New Targets and Treatments for Follicular Lymphoma Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,

More information

The case for maintenance rituximab in FL

The case for maintenance rituximab in FL New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P

More information

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus

More information

Rituximab in the Treatment of NHL:

Rituximab in the Treatment of NHL: New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,

More information

Brad S Kahl, MD. Tracks 1-21

Brad S Kahl, MD. Tracks 1-21 I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical

More information

Rituximab for the first-line treatment of stage III-IV follicular lymphoma

Rituximab for the first-line treatment of stage III-IV follicular lymphoma Rituximab for the first-line treatment of stage III-IV (review of guidance 110) Issued: January 2012 guidance.nice.org.uk/ta243 NICE has accredited the process used by the Centre for Health Technology

More information

148 P&T March 2010 Vol. 35 No. 3

148 P&T March 2010 Vol. 35 No. 3 Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin s Lymphoma Efrat Dotan, MD, Charu Aggarwal, MD, MPH, and Mitchell R. Smith, MD, PhD ABSTRACT Non-Hodgkin s lymphoma (NHL) is the most

More information

NCCP Chemotherapy Protocol. Maintenance therapy for the treatment of follicular CD20 positive, B-cell NHL patients responding to induction therapy.

NCCP Chemotherapy Protocol. Maintenance therapy for the treatment of follicular CD20 positive, B-cell NHL patients responding to induction therapy. RiTUXimab 375mg/m 2 Therapy-Follicular Lymphoma INDICATIONS FOR USE: INDICATION Maintenance therapy for the treatment of follicular CD20 positive, B-cell NHL patients responding to induction therapy. Monotherapy

More information

landmarks Lymphoma STUDY SUMMARY: Immediate use of rituximab may change standard of care

landmarks Lymphoma STUDY SUMMARY: Immediate use of rituximab may change standard of care Lymphoma Improving Time to Initiation of New Therapy Douglas Stewart, MD, FRCPC, Chief, Division of Hematology & Hematologic Malignancies, University of Calgary; Provincial Leader, Hematology Tumour Team,

More information

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.

More information

Address correspondence to: Brad S. Kahl, MD 1111 Highland Avenue, 4059 WIMR Madison, WI

Address correspondence to: Brad S. Kahl, MD 1111 Highland Avenue, 4059 WIMR Madison, WI Yttrium 90-Ibritumomab Tiuxetan Plus Rituximab Maintenance as Initial Therapy for Patients With High-Tumor-Burden Follicular Lymphoma: A Wisconsin Oncology Network Study Saurabh Rajguru, MD, Thorhildur

More information

FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?

FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital

More information

12 th Annual Hematology & Breast Cancer Update Update in Lymphoma

12 th Annual Hematology & Breast Cancer Update Update in Lymphoma 12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma

More information

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma

Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)

More information

Jonathan W Friedberg, MD, MMSc

Jonathan W Friedberg, MD, MMSc I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer

More information

Rituximab maintenance therapy of follicular lymphoma in clinical practice

Rituximab maintenance therapy of follicular lymphoma in clinical practice Received: 20 December 2017 Revised: 10 April 2018 DOI: 10.1002/cam4.1549 Accepted: 19 April 2018 ORIGINAL RESEARCH Rituximab maintenance therapy of follicular lymphoma in clinical practice Ulrich Dührsen

More information

Gazyva (obinutuzumab)

Gazyva (obinutuzumab) STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination

More information

Antibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma

Antibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma Antibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma Steven I. Park, MD, 1* and Kristy L. Richards, PhD, MD 1 ABSTRACT Antibody-based immunotherapeutic agents have emerged as important

More information

Patterns of Care in Medical Oncology. Follicular Lymphoma

Patterns of Care in Medical Oncology. Follicular Lymphoma Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy

More information

NCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12

NCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12 NCCN Non Hodgkin s Lymphomas Guidelines V.1.213 Update Meeting 6/14/12 and 6/15/12 Guidelines Page and Request Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Panel Discussion References

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Gazyva) Reference Number: CP.PHAR.305 Effective Date: 02.01.17 Last Review Date: 11.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important Reminder

More information

eastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning

eastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy

More information

RITUXAN (rituximab and hyaluronidase human)

RITUXAN (rituximab and hyaluronidase human) Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria

More information

Thessaloniki, Greece PLEASE SCROLL DOWN FOR ARTICLE

Thessaloniki, Greece PLEASE SCROLL DOWN FOR ARTICLE This article was downloaded by:[heal-link Consortium] On: 27 July 2008 Access Details: [subscription number 772810551] Publisher: Informa Healthcare Informa Ltd Registered in England and Wales Registered

More information

RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA

RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin

More information

CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE

CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE FOR IMMEDIATE RELEASE CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE Results of Studies of BEXXAR TM Therapy Show Promise

More information

How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES

How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account

More information

Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta243

Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta243 Rituximab for the first-line treatment of stage III-IV follicular lymphoma Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta243 NICE 2017. All rights reserved. Subject to

More information

Biogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development

Biogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development Biogen Idec Oncology Pipeline Greg Reyes, MD, PhD SVP, Oncology Research & Development March 25, 2009 Biogen Idec Strategy in Lymphoma / Leukemia CLL RITUXAN NHL FC-RITUXAN GA101 RITUXAN-CVP RITUXAN-CHOP

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 ARZERRA 100 mg, concentrate for solution for infusion B/3 (CIP code: 577 117-9) B/10 (CIP code: 577

More information

SEQUENCING FOLLICULAR LYMPHOMA

SEQUENCING FOLLICULAR LYMPHOMA SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial

More information

Disclosures WOJCIECH JURCZAK

Disclosures WOJCIECH JURCZAK Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA

More information

Indolent Lymphomas: Current. Dr. Laurie Sehn

Indolent Lymphomas: Current. Dr. Laurie Sehn Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard

More information

Monoclonal Antibody Therapy in Lymphoid Malignancies. The Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, Tennessee, USA

Monoclonal Antibody Therapy in Lymphoid Malignancies. The Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, Tennessee, USA The Oncologist Promising New Drugs and Combinations Monoclonal Antibody Therapy in Lymphoid Malignancies JOHN D. HAINSWORTH The Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, Tennessee,

More information

Update: New Treatment Modalities

Update: New Treatment Modalities ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant

More information

TRANSPARENCY COMMITTEE OPINION. 27 January 2010

TRANSPARENCY COMMITTEE OPINION. 27 January 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1

More information

Monoclonal Antibodies in Advanced B- cell Lymphomas

Monoclonal Antibodies in Advanced B- cell Lymphomas Monoclonal Antibodies in Advanced B- cell Lymphomas By Chaitra Ujjani, MD Bruce D. Cheson, MD Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, DC February 9, 2010 Financial

More information

Advances in the management of follicular lymphoma

Advances in the management of follicular lymphoma Hematology Meeting Reports 2007; 1(5):43 51 Advances in the management of follicular lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland, Oncologia medica, Bellinzona, Switzerland Corresponding

More information

Overview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC

Overview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC 2 A C A N A D I A N P E R S P E C T I V E Volume 2 November 2005 Overview The International Conference on Malignant Lymphoma (ICML) is held every three years in Lugano, Switzerland. ICML started nearly

More information

Expanding the Horizons )N 3UPPORTIVE #ARE /NCOLOGY. Communiqué from ICML 2008

Expanding the Horizons )N 3UPPORTIVE #ARE /NCOLOGY. Communiqué from ICML 2008 C A n a d i a n V i s i o n f o r O n c o l o g y )N 3UPPORTIVE #ARE /NCOLOGY Number 10 July 2008 PUBLICATIONS MAIL AGREEMENT NO. 41495516 RETURN UNDELIVERABLE CANADIAN ADDRESSES TO NEW EVIDENCE 4133 DUNDAS

More information

Notification to Implement Issued by pcodr: December 14, 2012

Notification to Implement Issued by pcodr: December 14, 2012 PROVINCIAL FUNDING SUMMARY Bendamustine hydrochloride (Treanda) for indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (first-line and relapsed/refractory) perc Recommendation: Recommends For further

More information

Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial

Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the

More information

CLINICAL STUDY PROTOCOL PRIMA. Primary Rituximab and Maintenance

CLINICAL STUDY PROTOCOL PRIMA. Primary Rituximab and Maintenance CLINICAL STUDY PROTOCOL PRIMA Primary Rituximab and Maintenance A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance

More information

GENENTECH AND BIOGEN IDEC RECEIVE A COMPLETE RESPONSE FROM FDA FOR EARLIER USE OF RITUXAN FOR RHEUMATOID ARTHRITIS

GENENTECH AND BIOGEN IDEC RECEIVE A COMPLETE RESPONSE FROM FDA FOR EARLIER USE OF RITUXAN FOR RHEUMATOID ARTHRITIS NEWS RELEASE Genentech Contacts: Media / Advocacy: Megan Pace (650) 467-7334 Investor: Susan Morris (650) 225-6523 Karl Mahler 011 41 61 68785 03 Biogen Idec Contacts: Media: Amy Reilly (617) 914-6524

More information

Rituximab, recombinant for intravenous infusion (CAS registry number: ).

Rituximab, recombinant for intravenous infusion (CAS registry number: ). MABTHERA Rituximab, recombinant for intravenous infusion (CAS registry number: 174722-31-7). WARNING Use of MABTHERA may be associated with an increased risk of progressive multifocal leukoencephalopathy

More information

Rituximab dosing in B cell lymphoma

Rituximab dosing in B cell lymphoma RESEARCH HIGHLIGHT Rituximab dosing in B cell lymphoma Yazeed Sawalha, Mitchell R. Smith Department of Medical Oncology and Hematology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland,

More information

B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma

B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is

More information

Lymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University

Lymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies

More information

Chronic Lymphocytic Leukemia Update. Learning Objectives

Chronic Lymphocytic Leukemia Update. Learning Objectives Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend

More information

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre

CARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS

More information

Rituximab as maintenance therapy for patients with follicular lymphoma (Review)

Rituximab as maintenance therapy for patients with follicular lymphoma (Review) Rituximab as maintenance therapy for patients with follicular lymphoma (Review) Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O This is a reprint of a Cochrane review, prepared and maintained by The

More information

pan-canadian Oncology Drug Review Initial Clinical Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma August 30, 2018

pan-canadian Oncology Drug Review Initial Clinical Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma August 30, 2018 pan-canadian Oncology Drug Review Initial Clinical Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma August 30, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

More information

London Cancer New Drugs Group APC/DTC Briefing

London Cancer New Drugs Group APC/DTC Briefing London Cancer New Drugs Group APC/DTC Briefing Rituximab for Mantle Cell Lymphoma g Contents Summary Summary & Background 1-2 Introduction 3 Discussion points/issues for Consideration 9 References 12 Background

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): October 29, 2002 Most Recent Review Date (Revised): March 25, 2014 Effective Date: August 6, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT

More information

MMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE

MMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar

More information

Traditional Therapies for Waldenstrom s Macroglobulinemia. Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014

Traditional Therapies for Waldenstrom s Macroglobulinemia. Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014 Traditional Therapies for Waldenstrom s Macroglobulinemia Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014 Jeff Atlin (1953-2014) Standard treatment options Single drug therapies

More information

Vesicular Demyelination in MS A Pattern of Humoral Immune Pathology Multiple Sclerosis: B-Cells Take Center Stage

Vesicular Demyelination in MS A Pattern of Humoral Immune Pathology Multiple Sclerosis: B-Cells Take Center Stage Vesicular Demyelination in MS A Pattern of Humoral Immune Pathology Multiple Sclerosis: B-Cells Take Center Stage Stephen L. Hauser, M.D. CD2 B cells in an MS lesion CD2 B cells in an MS lesion 1 CD138

More information

Economic impact of disease progression in follicular non-hodgkin lymphoma

Economic impact of disease progression in follicular non-hodgkin lymphoma Leukemia & Lymphoma, November 2011; 52(11): 2117 2123 2011 Informa UK, Ltd. ISSN: 1042-8194 print / 1029-2403 online DOI: 10.3109/10428194.2011.592623 ORIGINAL ARTICLE: CLINICAL Economic impact of disease

More information

Medication Policy Manual. Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010

Medication Policy Manual. Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010 Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru196 Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010 Committee Approval Date: January

More information

Anti-CD20 Monoclonal Antibody as a New Treatment Modality for B-Cell Lymphoma

Anti-CD20 Monoclonal Antibody as a New Treatment Modality for B-Cell Lymphoma Acta Histochem. Cytochem. 35 (4): 275 279, 2002 Review Anti-CD20 Monoclonal Antibody as a New Treatment Modality for B-Cell Lymphoma Tomomitsu Hotta 1 1 Division of Hematology and Oncology, Department

More information

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe

GLSG/OSHO Study Group. Supported by Deutsche Krebshilfe GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of

More information

Challenges in the Treatment of Follicular Lymphoma

Challenges in the Treatment of Follicular Lymphoma Challenges in the Treatment of Follicular Lymphoma Prof. Michele Ghielmini Clinical Director Oncology Institute of Southern Switzerland Bellinzona ESMO guidelines 2014 (simplified) Low tumor burden High

More information

Rituximab in Lymphoma and Chronic Lymphocytic Leukemia: A Clinical Practice Guideline

Rituximab in Lymphoma and Chronic Lymphocytic Leukemia: A Clinical Practice Guideline A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Rituximab in Lymphoma and Chronic Lymphocytic Leukemia: A Clinical Practice Guideline A. Prica, F. Baldassarre,

More information

Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes

Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie

More information

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION VOLUME 23 NUMBER 15 MAY 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and

More information

Accurate Reporting of Adverse Events in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Accurate Reporting of Adverse Events in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma J u l y 2 0 1 1 w w w. c l i n i c a l a d v a n c e s. c o m V o l u m e 9, I s s u e 7, S u p p l e m e n t 1 5 Moderator Discussants Bruce D. Cheson, MD Head of Hematology Georgetown University Hospital

More information

Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages)

Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages) Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages) Reference: NHS England 1607 1 First published: TBC Prepared by NHS England

More information

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017

More information

Rituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario

Rituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario Cancer Treatment Reviews (2007) 33, 161 176 available at www.sciencedirect.com journal homepage: www.elsevierhealth.com/journals/ctrv ANTI-TUMOUR TREATMENT Rituximab in lymphoma: A systematic review and

More information

Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies

Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide

More information

YESCARTA (axicabtagene ciloleucel)

YESCARTA (axicabtagene ciloleucel) YESCARTA (axicabtagene ciloleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices

More information

How to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma

How to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma How to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma Peter A. Riedell, MD and Brad S. Kahl, MD Abstract Follicular lymphoma (FL) is the most common

More information

Current and future management of follicular lymphoma

Current and future management of follicular lymphoma Int J Hematol (2012) 96:544 551 DOI 10.1007/s12185-012-1202-y PROGRESS IN HEMATOLOGY Current and Future Management of Major Subtypes of Malignant Lymphoma Based on Clinical Trials Current and future management

More information

Roche s GAZYVARO approved in Switzerland for people with previously untreated follicular lymphoma which are in need of systemic treatment

Roche s GAZYVARO approved in Switzerland for people with previously untreated follicular lymphoma which are in need of systemic treatment Media Release Basel, 25 July 2017 Roche s GAZYVARO approved in Switzerland for people with previously untreated follicular lymphoma which are in need of systemic treatment Approval is based on phase III

More information

R/R DLBCL Treatment Landscape

R/R DLBCL Treatment Landscape An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,

More information

Role of antibody therapy in lymphoid malignancies

Role of antibody therapy in lymphoid malignancies Role of antibody therapy in lymphoid malignancies Claire E. Dearden * The Royal Marsden Hospital and Institute of Cancer Research, London, UK Introduction Accepted: August 26, 2007 *Correspondence to:

More information

OSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD

OSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin

More information

Emerging targeted therapies for follicular lymphoma A future without chemotherapy

Emerging targeted therapies for follicular lymphoma A future without chemotherapy Emerging targeted therapies for follicular lymphoma A future without chemotherapy Pier Luigi Zinzani Institute of Hematology L. e A. Seràgnoli University of Bologna FOLLICULAR LYMPHOMA: GENERAL ASPECTS

More information

APPROXIMATELY 50% of patients with non-

APPROXIMATELY 50% of patients with non- Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin s Lymphoma By J.M. Vose, B.K. Link, M.L. Grossbard, M. Czuczman, A. Grillo-Lopez,

More information

clinical practice guidelines

clinical practice guidelines Annals of Oncology 22 (Supplement 6): vi59 vi63, 2011 doi:10.1093/annonc/mdr388 Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

More information